20 June 2013
Keywords: verona, rpl554, enters, toxicology, study, uk-based, pharma
Article | 15 October 2007
UK-based Verona Pharma says that its novel anti-asthmatic compound, RPL554, is now entering a 28-day experimental inhalation toxicology
study to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
15 October 2007
19 June 2013
© 2013 thepharmaletter.com